CRP and ST Elevation Myocardial Infarction: Anti-interleukin 1 immunomodulatory agents targeting the inflammasome have been shown to reduce cardiovascular events in coronary atherosclerosis patients with abnormal high sensitivity CRP [36], to improve left ventricular remodelling in those with ST elevation myocardial infarction [37] and to treat patients with idiopathic recurrent acute pericarditis (IRAP) [38,39].